News Author: Christopher Palmer Publish date: August 1, 2018
The approval is only for patients with chronic liver disease who are scheduled to undergo either a medical or dental procedure.
News Author: Christopher Palmer Publish date: July 31, 2018
The drug achieved clinically relevant levels without the need for a loading or supplemental doses.
News Author: Christopher Palmer Publish date: July 31, 2018
Iobenguane I 131 injection is indicated for the treatment of rare adrenal tumors that are unresectable, have metastasized, and require systemic ant...
News Author: Christopher Palmer Publish date: July 24, 2018
Orilissa (elagolix) is the first FDA-approved oral treatment for moderate to severe endometriosis pain in more than a decade.
News Author: Christopher Palmer Publish date: July 20, 2018
The oral medication is the first and only FDA-approved treatment for relapsed/refractory AML with an IDH1 mutation.
News Author: Christopher Palmer Publish date: July 17, 2018
Canagliflozin (Invokana) showed early renal benefits in CREDENCE.
News Author: Christopher Palmer Publish date: July 16, 2018
Approval was based on metastasis-free survival of 36.6 months for those receiving enzalutamide versus 14.7 months for those receiving placebo.
News Author: Christopher Palmer Publish date: July 13, 2018
Although some stakeholders are interested in keeping it going, it’s unclear what that would look like and what role, if any, AHRQ would have.
News Author: Christopher Palmer Publish date: July 13, 2018
The combo is approved for microsatellite instability-high or mismatch repair deficient metastatic CRC that has progressed.
News Author: Christopher Palmer Publish date: July 12, 2018
The company seeks to treat AML patients ineligible for intensive chemotherapy.
News Author: Christopher Palmer Publish date: July 10, 2018
Although the FDA is still working to approve the product for general use, it authorized its use in combat-related emergency situations.
News Author: Christopher Palmer Publish date: July 6, 2018
An exception is made for geographic areas with high risk of mosquito-borne Zika transmission.
News Author: Christopher Palmer Publish date: July 6, 2018
The intensity of recorded audio commentary suggested the men took the computer simulation seriously.
News Author: Christopher Palmer Publish date: July 2, 2018
Aristada Initio, a long-acting injectable atypical antipsychotic, is the first on the market to have a 2-month dosing option.
News Author: Christopher Palmer Publish date: June 29, 2018
“This novel device is a less invasive treatment that expands the options available to patients.”
